At the 12th Annual New Orleans Summer Cancer Meeting, Jessica MacIntyre, ARNP, NP-C, AOCNP, Director, Clinical Operations, Office of the Director, and Co-Leader, Oncology Nurse Practitioner Fellowship Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, FL, discussed some of the most impactful supportive care abstracts from the 2017 American Society of Clinical Oncology (ASCO) annual meeting, as well as the potential implications of this new research in the field of nursing.
This section provides a quick update of symptomatic conditions in oncology and their management. Readers are invited to submit brief updates following the guidelines at www.JHOPonline.com.
Adolescents and young adults (AYAs) with cancer often wait too long to discuss their end-of-life preferences, or they do not discuss those preferences at all and pass away in a manner that is against their wishes.
Providers caring for dying patients should be prepared to discuss physician-assisted death (PAD).
This section provides a quick update of symptomatic conditions in oncology and their management.
Delaying medication processing is common, especially when it comes to oral cancer therapies. Oncologists at 3 oncology clinics looked at such barriers and the potential impact on patient outcomes.
Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading, according to a study presented by Paolo Bossi, MD, at the recent European Society for Medical Oncology Congress.
High Rates of Vancomycin-Resistant Enterococci Bacteremia Observed in Patients Receiving Allogeneic Hematopoietic Stem-Cell Transplant
Patients receiving allogeneic hematopoietic stem-cell transplant (HSCT) have high rates of vancomycin-resistant enterococci (VRE) upon admission for transplantation.
Adherence to infusional or injectable anticancer drugs is not problematic—as long as the patient gets the infusion or injection, adherence is assured—but adherence is an emerging problem with newer oral anticancer drugs.
Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading.
Page 1 of 20
Results 1 - 10 of 200
Results 1 - 10 of 200